Karuna Therapeutics creates and delivers medicines for people with psychiatric and neurological disorders, including its lead product candidate KarXT. KarXT is an oral modulator of muscarinic receptors in the Phase III clinical trial for treating acute psychosis and other related disorders such as dementia. The company collaborates with Eli Lilly and Company, Zai Lab (Shanghai) Co., Ltd, PureTech Health LLC, Charles River Laboratories, and PsychoGenics.